Prescient Therapeutics
- Short interest
- <0.01%
- 0.00 pp 30d
- as of 14 Apr 2026
- Reported shorts
- 11K
- Shares on issue
- 1.052B
Prescient Therapeutics (PTX) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $138.5KM (source: ASX (Markit))vs $225.6KM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 29 Oct 2026
- NPAT
- −$7.0Mvs −$7.3M (FY25)
- Yahoo Finance, as at 29 Oct 2026
- EPS (diluted)
- −$0.007vs −$0.009 (FY25)
- Yahoo Finance, as at 29 Oct 2026
- Rev YoY
- −38.6%FY
- EPS YoY
- n/aFY
- ASX (Markit)
Summary of Appendix 4E and 2026 Annual Report, 21 Aug 2026
Prescient Therapeutics reported a net loss of $7.0 million for FY2026, a 4.4% improvement from the prior year's $7.3 million loss. No dividends were paid or declared. The company's cash runway extends into 2027, supported by $9.8 million in capital raisings and a $4.3 million R&D tax incentive, with the Phase 2a trial for PTX-100 progressing to 12 active sites and 26 patients enrolled.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 28 Oct 2026
- Gross margin
- n/a
- Operating margin
- −7,647.5%
- Net margin
- −5,056.4%
- FCF margin
- −5,216.4%
- ROE
- −54.7%
- ROA
- −45.4%
- FCF conversion
- n/a
- Net cash (excl. leases)
- $9.0M
- Net debt / EBITDA
- n/a
- Current ratio
- 7.1×
- Interest cover
- −989.9×
- Cash dividends paid / net profit
- n/a
- Market cap
- $54.7M
- P/E
- n/a
- P/B
- 3.9×
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance and ASX (Markit), as at 29 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $138.5KM (source: ASX (Markit)) | $225.6KM (source: ASX (Markit)) | $687.6KM (source: ASX (Markit)) | $459.1KM (source: ASX (Markit)) |
| Operating income | −$10.6M | −$11.9M | −$10.9M | −$9.9M |
| EBITDA | −$7.0M | −$11.9M | −$10.9M | −$9.9M |
| EBIT | −$7.0M | −$11.9M | −$10.9M | −$9.9M |
| Interest expense | $10.7K | n/a | n/a | n/a |
| Pretax income | −$7.0M | −$7.3M | −$8.2M | −$7.0M |
| Tax | $0 | $0 | $0 | $0 |
| NPAT | −$7.0M | −$7.3M | −$8.2M | −$7.0M |
| Net interest income | $127.8K | $225.6K | $687.6K | $459.1K |
| EPS basic | −$0.007 | −$0.009 | −$0.010 | −$0.010 |
| EPS diluted | −$0.007 | −$0.009 | −$0.010 | −$0.010 |
| Shares | 1.05B | 805.3M | 805.3M | 805.3M |
- ASX (Markit)
Financial reports
The company's own filings, newest first
- September 2026 Quarterly Update and Appendix 4CQuarterly Report13 Oct 2026via asx_announcements
- Appendix 4E and 2026 Annual ReportAnnual Results21 Aug 2026via asx_announcements
- June 2026 Quarterly Update and Appendix 4CQuarterly Report27 Jul 2026via asx_announcements
- March 2026 Quarterly Update and Appendix 4CQuarterly Report30 Apr 2026via asx_announcements
- Appendix 4D and Half Year Financial ReportHalf Year Results24 Feb 2026via asx_announcements
- December 2025 Quarterly Update and Appendix 4CQuarterly Report30 Jan 2026via asx_announcements
- September Quarterly Updated and Appendix 4CQuarterly Report10 Oct 2025via asx_announcements
- Appendix 4E and 2025 Annual ReportAnnual Results20 Aug 2025via asx_announcements
- June 2025 Quarterly Update and Appendix 4CQuarterly Report30 Jul 2025via asx_announcements
- March 2025 Quarterly Update and Appendix 4CQuarterly Report28 Apr 2025via asx_announcements
Showing 10 of 20 reports